RegulatoryOfficial

UK confirms plan to widen gene therapy definition to cover synthetic and genome-editing products

🇬🇧 MHRA · Thu 19 Nov 2026

Following a consultation backed by 83% of respondents, the government will amend the Human Medicines Regulations 2012 so more synthetic and gene-editing medicines fall under the advanced therapies framework.

The UK government confirmed on 19 November 2026 that it will modernise the legal definition of gene therapy medicinal products (GTMPs). The aim is to bring certain synthetic gene therapies and novel genome-editing treatments within the established advanced therapies framework. The announcement was made at the inaugural DIA-MHRA Global Summit in London, held on 16-17 November as part of London Life Sciences Week.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: MHRA ↗

Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.